Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,intangibleAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,marketState,shortName,market,exchangeDataDelayedBy,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,ECOR,26031814.0,48544400,498965,,-5383832,635610,-5383832,5724588,839857,-5383696,-5383696,,,,,,0,1203844,6587540,363987,-136,,-5383832,-5383832,138464624.0,7082795.0,26031814.0,33750219.0,48493.0,-112373980.0,-107323.0,5434966.0,9064385.0,5344993.0,545551.0,-107323.0,722415.0,27592838.0,16388339.0,259319.0,863799.0,944715.0,2110288.0,,1917270.0,31589.0,1917270.0,6920350.0,-40835.0,6920350.0,4822448.0,140500.0,-4155672.0,95680.0,118889.0,11227.0,1011610.0,,22247845.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636541940,1636977600,-0.482,-0.34,-0.31,-3.3387096,0.537,1.0120555,0.02294445,0.022671139,1.6414421,-0.6064421,-0.3694569,50243452,-3.0441175,1.9273742,15,America/New_York,EDT,-14400000,4,0.48543644,1.03 - 1.04,1.03,1.03,1.04,11,30,finmb_224595724,REGULAR,"electroCore, Inc.",us_market,0,NMS,False,False,1.035,1630507371,0.004999995,1.03,1.04,1.03,70195,NasdaqGS,"electroCore, Inc.",USD,2702684,1330700,0.13,0.1436464,0.905 - 3.63,-2.5950003,-0.71487606,0.905,3.63,1.31,,,3.63,0.905,1.0121,1.6414,2.7M,1.33M,48.54M,,41.44M,26.21%,13.13%,966.59k,1.87,2.05%,1.99%,750.02k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-541.16%,-44.63%,-94.30%,3.97M,0.09,64.10%,1.76M,-21.35M,-20.94M,-0.4820,,25.45M,0.52,2.82M,10.58,5.16,0.54,-15.77M,-12.49M,Value,07866,Healthcare,45,"electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.",Rockaway,973 290 0097,NJ,1609372800,United States,http://www.electrocore.com,86400,200 Forge Way,973 290 9171,Medical Instruments & Supplies,Suite 205
t-1,ECOR,22209762.0,48544400,1018633,,-6323769,635610,-6323769,4856385,109331,-5765687,-5765687,,,,,,0,928265,6693952,818934,-558082,,-6323769,-6323769,130205027.0,7873581.0,23008972.0,31518163.0,45560.0,-106990148.0,-251467.0,4893982.0,4241937.0,5890302.0,476236.0,-251467.0,761304.0,25063667.0,18386160.0,270546.0,1097946.0,876436.0,2078699.0,799210.0,3703218.0,50260.0,3703218.0,-139682.0,199314.0,350000.0,409483.0,-62664.0,-3091389.0,40134.0,751559.0,-94592.0,2215186.0,-489682.0,19173365.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636541940,1636977600,-0.482,-0.34,-0.31,-3.3387096,0.537,1.0120555,0.02294445,0.022671139,1.6414421,-0.6064421,-0.3694569,50243452,-3.0441175,1.9273742,15,America/New_York,EDT,-14400000,4,0.48543644,1.03 - 1.04,1.03,1.03,1.04,11,30,finmb_224595724,REGULAR,"electroCore, Inc.",us_market,0,NMS,False,False,1.035,1630507371,0.004999995,1.03,1.04,1.03,70195,NasdaqGS,"electroCore, Inc.",USD,2702684,1330700,0.13,0.1436464,0.905 - 3.63,-2.5950003,-0.71487606,0.905,3.63,1.31,,,3.63,0.905,1.0121,1.6414,2.7M,1.33M,48.54M,,41.44M,26.21%,13.13%,966.59k,1.87,2.05%,1.99%,750.02k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-541.16%,-44.63%,-94.30%,3.97M,0.09,64.10%,1.76M,-21.35M,-20.94M,-0.4820,,25.45M,0.52,2.82M,10.58,5.16,0.54,-15.77M,-12.49M,Value,07866,Healthcare,45,"electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.",Rockaway,973 290 0097,NJ,1609372800,United States,http://www.electrocore.com,86400,200 Forge Way,973 290 9171,Medical Instruments & Supplies,Suite 205
t-2,ECOR,28260416.0,48544400,629002,,-4486404,635610,-4486404,4592936,733337,-4488601,-4488601,,,,,,0,1080841,5569442,347504,2197,,-4486404,-4486404,129071951.0,8179295.0,28260416.0,37075321.0,45199.0,-100666379.0,-190355.0,7053299.0,3832454.0,5811619.0,732305.0,-190355.0,1421488.0,28600534.0,22135211.0,175954.0,1331559.0,793216.0,2028439.0,,-18167772.0,155525.0,-18167772.0,11833802.0,-1102702.0,11180462.0,-11030674.0,-84568.0,-4612136.0,24383.0,42364.0,-56468.0,740647.0,653340.0,22788915.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636541940,1636977600,-0.482,-0.34,-0.31,-3.3387096,0.537,1.0120555,0.02294445,0.022671139,1.6414421,-0.6064421,-0.3694569,50243452,-3.0441175,1.9273742,15,America/New_York,EDT,-14400000,4,0.48543644,1.03 - 1.04,1.03,1.03,1.04,11,30,finmb_224595724,REGULAR,"electroCore, Inc.",us_market,0,NMS,False,False,1.035,1630507371,0.004999995,1.03,1.04,1.03,70195,NasdaqGS,"electroCore, Inc.",USD,2702684,1330700,0.13,0.1436464,0.905 - 3.63,-2.5950003,-0.71487606,0.905,3.63,1.31,,,3.63,0.905,1.0121,1.6414,2.7M,1.33M,48.54M,,41.44M,26.21%,13.13%,966.59k,1.87,2.05%,1.99%,750.02k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-541.16%,-44.63%,-94.30%,3.97M,0.09,64.10%,1.76M,-21.35M,-20.94M,-0.4820,,25.45M,0.52,2.82M,10.58,5.16,0.54,-15.77M,-12.49M,Value,07866,Healthcare,45,"electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.",Rockaway,973 290 0097,NJ,1609372800,United States,http://www.electrocore.com,86400,200 Forge Way,973 290 9171,Medical Instruments & Supplies,Suite 205
t-3,ECOR,20907242.0,48544400,1030530,,-5912418,635610,-4741528,5273329,479969,-5823890,-5823890,,,,,,-1170890,752955,6576845,272986,-88528,,-4741528,-4741528,117154945.0,7115764.0,20907242.0,28658616.0,38815.0,-96179975.0,-106543.0,7201851.0,14863128.0,5075882.0,,-106543.0,1536012.0,19920753.0,3997208.0,119486.0,858114.0,761301.0,1872914.0,,-3998604.0,-224749.0,-3998604.0,7369625.0,-372646.0,5959101.0,-757368.0,-107696.0,-4020693.0,25750.0,-57648.0,152558.0,1127052.0,1410524.0,14844871.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1620331200,1636541940,1636977600,-0.482,-0.34,-0.31,-3.3387096,0.537,1.0120555,0.02294445,0.022671139,1.6414421,-0.6064421,-0.3694569,50243452,-3.0441175,1.9273742,15,America/New_York,EDT,-14400000,4,0.48543644,1.03 - 1.04,1.03,1.03,1.04,11,30,finmb_224595724,REGULAR,"electroCore, Inc.",us_market,0,NMS,False,False,1.035,1630507371,0.004999995,1.03,1.04,1.03,70195,NasdaqGS,"electroCore, Inc.",USD,2702684,1330700,0.13,0.1436464,0.905 - 3.63,-2.5950003,-0.71487606,0.905,3.63,1.31,,,3.63,0.905,1.0121,1.6414,2.7M,1.33M,48.54M,,41.44M,26.21%,13.13%,966.59k,1.87,2.05%,1.99%,750.02k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-541.16%,-44.63%,-94.30%,3.97M,0.09,64.10%,1.76M,-21.35M,-20.94M,-0.4820,,25.45M,0.52,2.82M,10.58,5.16,0.54,-15.77M,-12.49M,Value,07866,Healthcare,45,"electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.",Rockaway,973 290 0097,NJ,1609372800,United States,http://www.electrocore.com,86400,200 Forge Way,973 290 9171,Medical Instruments & Supplies,Suite 205
